Proposed Final Judgment and Competitive Impact Statement; United States v. Bluefield Regional Medical Center, Inc. and Princeton Community Hospital Associations, Inc., 17117-17123 [05-6536]
Download as PDF
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
Proposed Final Judgment and
Competitive Impact Statement; United
States v. Bluefield Regional Medical
Center, Inc. and Princeton Community
Hospital Associations, Inc.
Notice is hereby given pursuant to the
Antitrust Procedures and Penalties Act,
15 U.S.C. section 16(b)–(h), that a
proposed Final Judgment, Stipulation,
and Competitive Impact Statement have
been filed with the United States
District Court for the Southern District
of West Virginia in United States v.
Bluefield Regional Medical Center, Inc.
and Princeton Community Hospital
Association, Inc., Civil Case No. 1:05–
0234. On March 21, 2005, the United
States filed a Complaint alleging that, on
January 30, 2003, Bluefield Regional
Medical Center, Inc. (BRMC) and
Princeton Community Hospital
Association, Inc. (PCH) entered into two
agreements in which BRMC agreed not
to offer many cancer services and PCH
agreed not to offer cardiac-surgery
services. The BRMC–PCH agreements
effectively allocated markets for cancer
and cardiac-surgery services and
restrained competition to the detriment
of consumers in violation of section 1 of
the Sherman Act.
The proposed Final Judgment filed
with the Complaint will enjoin BRMC
and PCH from enforcing the BRMC–PCH
agreements. BRMC and PCH also will be
enjoined from entering into, continuing,
maintaining, or enforcing any agreement
to allocate markets, territories, or
customers concerning cancer services or
cardiac surgery. In addition, BRMC and
PCH will be enjoined from entering into,
continuing, maintaining, or enforcing
any other agreement that (1) prohibits or
restricts a health-care facility from
obtaining a certificate of need relating to
cancer services or cardiac surgery or (2)
otherwise prohibits or restricts a healthcare facility from taking actions related
to providing cancer services or cardiac
surgery without prior notice to and prior
written approval of the United States.
Finally, BRMC and PCH are enjoined
from entering into, continuing,
maintaining, or enforcing any agreement
with each other concerning cancer
services or cardiac surgery without prior
notice to and prior written approval of
the United States.
Copies of the Complaint, proposed
Final Judgment, and Competitive Impact
Statement are available for inspection at
the Department of Justice, Antitrust
Documents Group, 325 Seventh Street,
NW., Room 215 North, Washington, DC
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
20530 and at the Office of the Clerk of
the United States District Court for the
Southern District of West Virginia, 601
Federal Street, Room 2303, Bluefield,
West Virgina 24701.
Public comment is invited within 60
days of the date of this notice. Such
comments, and responses thereto, will
be published in the Federal Register
and filed with the Court. Comments
should be directed to Mark J. Botti,
Chief, Litigation I Section, Antitrust
Division, U.S. Department of Justice,
1401 H Street, NW., Suite 4000,
Washington, DC 20530 (Telephone (202)
307–0001).
Dorothy B. Fountain,
Deputy Director of Operations, Antitrust
Division.
Final Judgment
Whereas, Plaintiff, the United States
of America, filed its Complaint on
March 21, 2005 alleging that
Defendants, Bluefield Regional Medical
Center, Inc. and Princeton Community
Hospital Association, Inc., entered into
agreements in violation of section 1 of
the Sherman Act, 15 U.S.C. 1, and
Plaintiff and Defendants, by their
respective attorneys, have consented to
the entry of this Final Judgment without
trial or adjudication of any issue of fact
or law, and without this Final Judgment
constituting any evidence against, or
any admission by, any party regarding
any such issue of fact or law;
And whereas, Defendants agree to be
bound by the provisions of the Final
Judgment pending its approval by this
Court;
And whereas, the essence of this Final
Judgment is to enjoin the Defendants
from allocating markets for the
provision of certain medical services
and to restore lost competition as
alleged in the Complaint;
And whereas, the United States
requires Defendants to agree to certain
procedures and prohibitions for the
purpose of restoring the loss of
competition alleged in the Complaint;
Now therefore, before any testimony
is taken, without trial or adjudication of
any issue of fact or law, and upon
consent of the parties, it is ordered,
adjudged and decreed:
I. Jurisdiction
This Court has jurisdiction over the
subject matter of and each of the parties
to this action. The Complaint states a
claim upon which relief may be granted
against Defendants under section 1 of
the Sherman Act, as amended (15 U.S.C.
1).
II. Definitions
As used in this Final Judgment:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
17117
A. ‘‘Agreement’’ means any kind of
formal or informal agreement,
arrangement, contract, understanding,
memorandum of understanding, interim
contract, contract appendix, addendum,
attachment, amendment, waiver, or
modification. Agreements that solely
concern patient-treatment protocols or
the transfer of patients necessary to
render patient care that is unavailable at
BRMC or PCH shall not be deemed an
agreement within the scope of this Final
Judgment. An agreement solely for the
merger of BRMC and PCH, the
acquisition by one of the other, or
bringing all or substantially all of the
operations or assets of BRMC and PCH
under common control shall not be
deemed an agreement within the scope
of this Final Judgment if BRMC and
PCH give at least thirty days advance
notice of such merger, acquisition, or
transaction to the United States.
B. ‘‘BRMC’’ means Defendant
Bluefield Regional Medical Center, Inc.
a non-profit corporation organized and
existing under the laws of the State of
West Virginia with its headquarters in
Bluefield, West Virginia, its successors
and assigns, and its subsidiaries,
divisions, groups, affiliates,
partnerships and joint ventures, and
their directors, officers, managers,
agents, and employees.
C. ‘‘Cancer and Open-Heart
Agreements’’ means (1) the contract
dated January 30, 2003 between BRMC
and PCH concerning cancer services and
all amendments and other agreements
ancillary to that contract and (2) the
contract dated January 30, 2003 among
BRMC, PCH, and Charleston Area
Medical Center, Inc. concerning cardiac
surgery and all amendments and other
agreements ancillary to that contract.
D. ‘‘Cancer Services’’ means any
health or other service relating to any
service performed by cancer specialists
such as radiation oncologists, medical
oncologists, surgical oncologists,
gynecological oncologists, and other
oncologic physician specialists. This
term includes any equipment,
technology, or modality used in
providing such services.
E. ‘‘Cardiac Surgery’’ means any
health or other services relating to
surgery on the heart or major blood
vessels of the heart (including both open
and closed heart surgery) and
therapeutic cardiac catherization. This
term includes any service, equipment,
technology, or modality relating to the
services of an open-heart surgeon,
cardiovascular surgeon, cardiovascular
anesthesiologist, interventional
cardiologist, or perfusionist.
F. ‘‘Certificate of Need’’ means
certificate of need as recognized by the
E:\FR\FM\04APN1.SGM
04APN1
17118
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
State of West Virginia (W. Va. Code
§ 16–2D–1 et seq.) and a certificate of
public need as recognized in the
Commonwealth of Virginia (Va. Code
Ann. § 32.1–102.1 et seq.).
G. ‘‘Health-Care Facility’’ means any
facility providing health-care services,
including hospitals, hospital-owned or
managed physician practices,
ambulatory-care centers, clinics, urgentcare centers, free-standing emergencycare centers, and ambulatory-surgery
centers.
H. ‘‘PCH’’ means Defendant Princeton
Community Hospital Association, Inc., a
non-profit corporation organized and
existing under the laws of the State of
West Virginia with its headquarters in
Princeton, West Virginia, its successors
and assigns, and its subsidiaries,
divisions, groups, affiliates,
partnerships and joint ventures, and
their directors, officers, managers,
agents, and employees.
I. The terms ‘‘and’’ and ‘‘or’’ have
both conjunctive and disjunctive
meanings.
III. Applicability
This Final Judgment applies to BRMC
and PCH, as defined above, and all other
persons in active concert or
participation with any of them who
receive actual notice of this Final
Judgment by personal service or
otherwise.
IV. Prohibited Conduct
A. BRMC and PCH are enjoined from
enforcing all or any part of the Cancer
and Open-Heart Agreements. BRMC’s
and PCH’s obligations under this Final
Judgment supersede their obligations
under either of these agreements, and
BRMC and PCH shall not object to the
performance of their obligations under
this Final Judgment on the grounds that
those obligations would cause them to
breach either agreement.
B. BRMC and PCH are enjoined from,
in any manner, directly or indirectly,
entering into, continuing, maintaining,
or enforcing any agreement to allocate
any cancer or cardiac-surgery service,
market, territory, or customer.
C. BRMC and PCH are enjoined from,
in any manner, directly or indirectly,
entering into, continuing, maintaining,
or enforcing any other agreement that
(1) prohibits or restricts a health-care
facility from obtaining a certificate of
need relating to cancer services or
cardiac surgery or (2) otherwise
prohibits or restricts a health-care
facility from taking actions related to
providing cancer services or cardiac
surgery without prior notice to and prior
written approval of the United States,
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
which will not be withheld
unreasonably.
D. BRMC and PCH are enjoined from,
in any manner, directly or indirectly,
entering into, continuing, maintaining,
or enforcing any agreement with each
other concerning cancer services or
cardiac surgery without prior notice to
and prior written approval of the United
States, which will not be withheld
unreasonably.
V. Compliance Inspection
A. For the purposes of determining or
securing compliance with this Final
Judgment, or of determining whether
the Final Judgment should be modified
or vacated, and subject to any legally
recognized privilege, from time to time
duly authorized representatives of the
United States Department of Justice,
including consultants and other persons
retained or designated thereby, shall,
upon written request of a duly
authorized representative of the
Assistant Attorney General in charge of
the Antitrust Division and on reasonable
notice to Defendants, be permitted:
1. Access during Defendants’ office
hours to inspect and copy, or at the
United States’ option, to require that
Defendants provide copies of, all books,
ledgers, accounts, records and
documents in their possession, custody,
or control relating to any matters
contained in this Final Judgment; and
2. To interview, either informally or
on the record, Defendants’ officers,
employees, or agents, who may have
their individual counsel present,
regarding such matters. The interviews
shall be subject to the reasonable
convenience of the interviewee and
without restraint or interference by
Defendants.
B. Upon the written request of a duly
authorized representative of the
Assistant Attorney General in charge of
the Antitrust Division, Defendants shall
submit written reports, under oath if
requested, relating to any of the matters
contained in this Final Judgment as may
be requested.
C. No information or documents
obtained by the means provided in this
section shall be divulged by Plaintiff to
any person other than an authorized
representative of the executive branch of
the United States except in the course
of legal proceedings to which the United
States is a party (including grand jury
proceedings), or for the purpose of
securing compliance with this Final
Judgment, or as otherwise required by
law.
D. If at the time Defendants furnish
information or documents to the United
States, they represent and identify in
writing the material in any such
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
information or documents to which a
claim of protection may be asserted
under Rule 26(c)(7) of the Federal Rules
of Civil Procedure, and mark each
pertinent page of such material,
‘‘Subject to claim of protection under
Rule 26(c)(7) of the Federal Rules of
Civil Procedure,’’ then the United States
shall give Defendants ten calendar days
notice prior to divulging such material
in any legal proceeding (other than a
grand jury proceeding).
VI. Retention of Jurisdiction
This Court retains jurisdiction to
enable any party to this Final Judgment
to apply to this Court at any time for
further orders and directions as may be
necessary or appropriate to carry out or
construe this Final Judgment, to modify
any of its provisions, to enforce
compliance, and to punish violations of
its provisions.
VII. Expiration of Final Judgment
Unless this Court grants an extension,
this Final Judgment shall expire ten
years from the date of its entry.
VIII. Correspondence
BRMC and PCH shall provide notice
and seek prior written approval as
contemplated by this Final Judgment by
sending correspondence to Chief,
Litigation I, Antitrust Division, United
States Department of Justice, 1401 H
Street, NW., Suite 4000, Washington,
DC 20530, or such other address as the
United States shall designate.
IX. Public Interest Determination
Entry of this Final Judgment is in the
public interest.
Court approval subject to procedures of
Antitrust Procedures and Penalties
Act, 15 U.S.C. § 16.
United States District Judge.
Stipulation
It is stipulated by and between the
undersigned parties, by their respective
attorneys, that:
1. The Court has jurisdiction over the
subject matter of this action and each of
the parties hereto, and venue of this
action is proper in this District.
2. The parties stipulate that a
proposed Final Judgment in the form
attached as Exhibit A may be entered by
the Court, upon the motion of any party
or upon the Court’s own motion, at any
time after compliance with the
requirements of the antitrust Procedures
and Penalties Act, 15 U.S.C. 16, and
without further notice to any party or
other proceedings, provided that the
United States has not withdrawn its
consent, which it may do at any time
before the entry of the proposed final
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
Judgment by serving notice thereof on
defendants and by filing that notice
with the Court.
3. Defendants shall abide by and
comply with the provisions of the
proposed Final Judgment, pending the
Judgment’s entry by the Court, or until
expiration of time for all appeals of any
Court ruling declining entry of the
proposed Final Judgment, and shall,
from the date of the signing of this
Stipulation by the parties, comply with
all the terms and provisions of the
proposed Final Judgment as though the
same were in full force and effect as an
order of the Court.
4. This Stipulation shall apply with
equal force and effect to any amended
proposed Final Judgment agreed upon
in writing by the parties and submitted
to the Court.
5. In the event (a) the United States
has withdrawn its consent, as provided
in section 2 above, or (b) the proposed
Final Judgment is not entered pursuant
to this Stipulation, the time has expired
for all appeals of any Court ruling
declining entry of the proposed Final
Judgment, and the Court has not
otherwise ordered continued
compliance with the terms and
provisions of the proposed Final
Judgment, then the parties are released
from all further obligations under this
Stipulation, and the making of this
Stipulation shall be without prejudice to
any party in this or any other
proceeding.
For Plaintiff United States of America:
Dated: March 21, 2005.
Peter J. Mucchetti, Esq.,
Litigation I Section, Antitrust Division,
United States Department of Justice.
For Defendant Bluefield Regional Medical
Center, Inc.:
Dated: March 18, 2005.
Arthur N. Lerner, Esq.,
Crowell & Moring LLP, Counsel for Defendant
Bluefield Regional Medical Center, Inc.
For Defendant Princeton Community
Hospital Association, Inc.
March 14, 2005.
Kevin E. Grady, Esq.,
Alston & Bird LLP, Counsel for Defendant
Princeton Community Hospital
Association, Inc.
Competitive Impact Statement
The United States of America,
pursuant to section 2(b) of the Antitrust
Procedures and Penalties Act,
(‘‘APPA’’), 15 U.S.C. 16(b)–(h), files this
Competitive Impact Statement relating
to the proposed Final Judgment
submitted for entry in this civil antitrust
proceeding.
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
17119
I. Nature and Purpose of the Proceeding
On March 21, 2005, the United States
filed a civil antitrust Complaint alleging
that Bluefield Regional Medical Center,
Inc. (BRMC) and Princeton Community
Hospital Association, Inc. (PCH) had
violated Section 1 of the Sherman Act,
15 U.S.C. 1. BRMC owns and operates
a 265-bed, general acute-care hospital in
Bluefield, West Virginia. PCH owns and
operates a 211-bed general acute-care
hospital in Princeton, West Virginia.
PCH also owns and operates St. Luke’s
Hospital, LLC (St. Luke’s), a 79-bed,
general acute-care hospital in Bluefield,
West Virginia.
The Complaint alleges that, on
January 30, 2003, BRMC and PCH
entered into two agreements (the
‘‘cancer and open-heart agreements’’) in
which BRMC agreed not to offer certain
cancer services and PCH agreed not to
offer certain cardiac-surgery services.
The cancer and open-heart agreements
effectively allocated markets for cancer
and cardiac-surgery services and
restrained competition to the detriment
of consumers. With the Complaint, the
United States, BRMC, and PCH filed an
agreed-upon proposed Final Judgment
that annuls the cancer and open-heart
agreements and prohibits BRMC and
PCH from taking actions that would
reduce competition between the two
hospitals for patients needing cancer
and cardiac-surgery services.
The United States, BRMC, and PCH
have agreed that the proposed Final
Judgment may be entered after
compliance with the APPA, provided
that the United States has not
withdrawn its consent. Entry of the
Final Judgment would terminate the
action, except that the Court would
retain jurisdiction to construe, modify,
or enforce the Final Judgment’s
provisions and to punish violations
thereof.
services. BRMC sought to develop
cardiac-surgery services since at least
1999. Similarly, from at least 1999 until
PCH agreed not to compete with BRMC
in cardiac-surgery services, PCH sought
to develop cardiac-surgery services by
working with other hospitals in
southern West Virginia.
The State of West Virginia and the
Commonwealth of Virginia require that
a hospital obtain a certificate of need or
a certificate of public need (collectively,
‘‘CON’’) from a state agency before a
hospital may provide either cardiacsurgery services or radiation-therapy
services (using a linear accelerator) for
treating patients with cancer. The West
Virginia Health Care Authority
(WVHCA) administers the CON program
in West Virginia. The Virginia
Department of Health’s Certificate of
Public Need Division and regional
health planning agencies administer the
CON program in Virginia.
In January 1999, BRMC submitted a
CON application to the WVHCA to
develop a cardiac-surgery program in
Mercer County, West Virginia. At that
time, neither BRMC, PCH, nor St. Luke’s
had a CON to operate a cardiac-surgery
program. PCH, St. Luke’s, and other
hospitals opposed BRMC’s application.
PCH and St. Luke’s argued, in part, that
BRMC’s application should be denied
because it did not provide a role for
PCH and St. Luke’s in the provision of
cardiac-surgery services in southern
West Virginia.
In February 2000, the WVHCA issued
a written decision that denied BRMC’s
application for a CON to develop a
cardiac-surgery program because BRMC
was unable to show that, without
working with other hospitals, it would
be able to attract a sufficient number of
patients. In its decision, the WVHCA
wrote that PCH, St. Luke’s and other
hospitals had:
II. Description of Practices and Events
Giving Rise to the Alleged Violations of
the Antitrust Laws
failed to successfully negotiate with [BRMC]
to reach a shared goal. The goal being to
provide advanced cardiology services to the
citizens of southern West Virginia and
southwestern Virginia * * *. [The WVHCA]
would have preferred that the parties work
together to present a project that could have
been approved under the existing law.
Instead, the parties fought among themselves,
failed to resolve their differences, and in
return, the citizens of southern West Virginia
will be inconvenienced and suffer by not
having a regional open-heart service
provider.
A. Services Provided by the Defendants
and Events Preceding the Parties’
Cancer and Open-Heart Agreements
At all times relevant to the matters
alleged in the Complaint, BRMC and
PCH have been significant competitors
in general acute-care hospital services
and in cancer services. PCH is located
about fifteen miles from BRMC. PCH’s
St. Luke’s Hospital is located about two
miles from BRMC. BRMC, PCH, and St.
Luke’s are the only general acute-care
hospitals in Mercer County, West
Virginia.
BRMC and PCH also have been
potential competitors in cardiac-surgery
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
On one or more occasions during
2002, BRMC and PCH representatives
met with WVHCA officials. The
WVHCA officials encouraged BRMC and
PCH to reach an understanding that
would enable the parties to submit an
application for an open-heart surgery
E:\FR\FM\04APN1.SGM
04APN1
17120
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
CON that the WVHCA would be able to
approve. The WVHCA officials,
however, neither instructed nor
encouraged BRMC and PCH to allocate
markets.
B. The Cancer and Open-Heart
Agreements
On January 30, 2003, BRMC and PCH
entered into the cancer and open-heart
agreements. The cancer agreement
concerned PCH’s provision of certain
cancer services, including radiationtherapy services, and the open-heart
agreement concerned BRMC’s plan to
develop cardiac-surgery services (openheart surgery and therapeutic cardiaccatheterization services). The
agreements applied to McDowell,
Mercer, Monroe, Raleigh, Summers, and
Wyoming counties in southern West
Virginia and Bland, Giles, and Tazewell
counties in western Virginia. In the
agreements, BRMC agreed to submit a
joint CON application with PCH to
transfer BRMC’s CON to operate
radiation-therapy equipment to PCH.
PCH agreed to submit a joint CON
application with BRMC for BRMC to
receive a cardiac-surgery CON.
As part of the cancer and open-heart
agreements, BRMC agreed to refrain
from competing with PCH in various
ways, none of which was related to a
procompetitive purpose. BRMC agreed,
among other things:
• Not to apply for, finance,
encourage, or participate in a CON to
provide cancer services by itself or with
any entity other than PCH;
• That, in the event that the State of
West Virginia or the Commonwealth of
Virginia no longer requires a CON to
provide cancer services, BRMC would
not develop, finance, encourage,
participants in, or support the
development or provision of cancer
services by BRMC or any entity other
than PCH;
• Not to engage in, support, finance,
encourage, or participate in the
recruitment of any physician cancer
specialists to BRMC’s medical staff or
for any other entity or individual, other
than PCH;
• To provide to PCH information
relating to cancer services provided by
BRMC;
• Not to market or advertise that
BRMC has a cancer center;
• Not to provide outpatient
chemotherapy services (except for those
services ordered or performed by either
of two physicians currently practicing at
BRMC);
• Not to lease space in its existing or
future medical office buildings to any
cancer specialists, except for those
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
cancer specialists leasing space as of the
date of the agreement; and
• That, in the event that any new
technology or modality for the diagnosis
or treatment of cancer becomes available
that is not offered generally at hospitals
similar to PCH and BRMC, BRMC would
not acquire, develop, offer or provide
such technology or modality, and BRMC
would not finance, encourage,
participate in, or support the
development or offering of such
technology or modality by any entity
other than PCH.
As part of the cancer and open-heart
agreements, PCH also agreed to refrain
from competing with BRMC is various
ways, none of which was related to a
procompetitive purpose. PCH agreed,
among other things:
• Not to apply for, finance,
encourage, or participate in a CON to
provide cardiac-surgery services by
itself or with any entity other than
BRMC;
• That, in the event that the State of
West Virginia or the Commonwealth of
Virginia no longer requires a CON to
provide cardiac-surgery services, PCH
would not develop, finance, encourage,
participate in, or support the
development or provision of cardiacsurgery services by PCH or any entity
other than BRMC;
• Not to engage in, support, finance,
encourage, or participate in the
recruitment of any cardiac-surgery
specialists to PCH’s medical staff or for
any other entity or individual, other
than BRMC;
• To provide to BRMC information
relating services provided by PCH;
• Not to solicit, entertain, finance,
aid, support, or participate in any
competing proposal from any entity or
physician to develop cardiac-surgery
services;
• Not to lease space in its existing or
future medical office buildings to any
open-heart surgery specialist; and
• That, in the event that any new
technology or modality for the diagnosis
or treatment or cardiovascular disease
becomes available that is not offered
generally at hospitals similar to PCH
and BRMC, PCH would not acquire,
develop, offer or provide such
technology or modality, and PCH would
not finance, encourage, participate in, or
support the development or offering of
such technology or modality by any
entity other than BRMC.
The term of the cancer and open-heart
agreements commend on January 30,
2003 and terminates five years after the
first open-heart surgery is performed at
BRMC or the first cancer patient is
treated at a PCH comprehensive cancer
center, whichever is later. Neither
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
agreement can last longer than eight
years. Each agreement automatically
terminates if, within three years from
commencement, either party has not
received all government approvals
needed to provide its services.
PCH and BRMC structured the
agreements such that PCH would
independently own its cancer-treatment
facilities and provide its cancer services
independently of BRMC, BRMC would
independently own its cardiac-surgery
facilities and provide its cardiac-surgery
services independently of PCH, and
BRMC and PCH would not provide
these services as part of a joint venture.
On January 23, 2003, BRMC
submitted to the WVHCA a CON
application, with PCH as a joint
applicant, to develop a cardiac-surgery
program at BRMC. On July 30, 2003,
PCH submitted to the WVHCA an
application, with BRMC as a joint
applicant, to transfer BRMC’s CON to
operate radiation-therapy equipment to
PCH. The WVHCA approved BRMC’s
cardiac-surgery CON application on
August 1, 2003. PCH’s application to
transfer BRMC’s radiation-therapy
equipment CON to PCH remains
pending with the WVHCA.
Because of the cancer and open-heart
agreements, BRMC and PCH have
refrained and, if not enjoined, likely
would continue to refrain from
competing to serve patients that need
cancer and cardiac-surgery services. The
cancer and open-heart agreements have
had and, unless enjoined, likely would
have the following harmful effects:
• Managed-care purchasers, their
enrollees and employees, and other
patients in southern West Virginia and
western Virginia have been denied and
would be denied the benefits of price
competition between PCH and BRMC;
• The quality of services has
decreased and likely would decrease in
the absence of competition between
PCH and BRMC to provide cancer and
cardiac-surgery services;
• Patients have lost and would lose
the ability to choose between PCH and
BRMC when selecting a hospital to
provide cancer services;
• Patients have lost and would lose
the benefit of potential competition
between PCH and BRMC in cardiacsurgery services; and
• PCH’s and BRMC’s incentives to
innovate or offer new cancer and
cardiac-surgery services have been and
would be decreased.
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
interests; affords adversely affected
parties the right of judicial review;
requires written findings as to whether
approval of a CON would further
legislatively established criteria; and
The state-action doctrine provides
establishes other procedural safeguards.
immunity from Federal antitrust
liability where a party can satisfy a two- W. Va. Code §§ 16–29B–12(f), 16–29B–
part test. First, the party must show that 13, and 16–2D–9. When reviewing CON
applications, the WVHCA must follow
the challenged restraint is one clearly
established procedures and act within
articulated and affirmatively expressed
as state policy. California Retail Liquor
the CON process. See W. Va. Code § 16–
Dealers Association v. Midcal
2D–1 et seq., W. Va. Code St. R. § 65–
Aluminum, 445 U.S. 97, 105 (1980). To
7–1 et seq., W. Va. Code § 16–29B–1 et
satisfy the clear-articulation
seq. The statutes and regulations
requirement, a defendant must show
delineating the responsibilities of the
only that ‘‘the legislature contemplated
WVHCA do not explicitly empower it to
the kind of action complained of.’’ Town consider, or to issue opinions
of Hallie v. City of Eau Claire, 471 U.S.
concerning, private market-allocation
34, 44 (1985). Second, the state must
agreements. See, e.g., W. Va. Code § 16–
actively supervise the challenged
2D–1 et seq., W. Va. Code St. R. § 65–
conduct. Midcal, 445 U.S. at 105.
7–1 et seq., W. Va. Code § 16–29B–1 et
As discussed below, no state action in
seq., W. Va. Code St. R. § 65–5–1 et seq.,
either West Virginia or Virginia shields
W. Va. Code St. R. § 65–26–1 et seq.
the cancer and open-heart agreements
Nor does the WVHCA have implicit
from federal antitrust review. The West
authority to approve private agreements
Virginia legislature has not enpowered
as a means of regulating competition. In
the WVHCA to authorize hospitals to
enter into market-allocation agreements. light of the rights and procedural
Furthermore, the WVHCA is not
safeguards afforded in the statutory
empowered to exercise, and has not
framework to affected parties, to
exercised, active supervision over the
conclude that WVHCA has implied
cancer and open-heart agreements.
authority to authorize private marketIndeed, the WVHCA did not purport to
allocation agreements would be
authorize the parties to enter into the
inconsistent with that framework and
agreements. Similarly, in Virginia, no
effectively would give to the WVHCA
state agency or official encouraged or
unreviewable discretion to regulate
authorized BRMC and PCH to reach an
health-care markets. To the contrary, the
understanding or agreement concerning legislature generally has left West
cardiac-surgery or cancer services.
Virginia health-care providers free to
1. The West Virginia Legislature Did Not make market decisions on how to
Empower the WVHCA To Authorize
compete as long as they are not (1)
Private Market-allocation Agreements
adding or expanding health-care
services; (2) incurring a capital
The West Virginia legislature
expenditure of $2 million or more; (3)
empowered the WVHCA to administer
West Virginia’s CON program according obtaining major medical equipment
valued at $2 million or more; or (4)
to legislatively established criteria. W.
Va. Code § 16–2D–1 et seq., W. Va. Code developing or acquiring new health-care
facilities. W. Va. Code § 16–2D–3.
St. R. § 65–7–1 et seq., W. Va. Code
§ 16–29B–1 et seq. Although the West
Because the West Virginia legislature
Virginia legislature granted the WVHCA has not granted to the WVHCA the
significant regulatory powers over
explicit authority to approve private
competition in West Virginia healthmarket-allocation agreements such as
care markets, it limited the means by
the cancer and open-heart agreements,
which the WCHCA can regulate
because any implicit authority of the
competition among health-care
WVHCA to approve such agreements
providers principally to granting or
would be inconsistent with the statutory
denying CONs to firms wishing to
framework that the legislature did
compete. W. Va. Code § 16–2D–1 et seq.,
create, and because the legislature
W. Va. Code St. R. § 65–7–1 et seq., W.
clearly contemplated that West Virginia
Va. Code § 16–29B–1 et seq.
hospitals would compete in the free
In administering the CON program,
market for many of the activities
the WVHCA is called upon to review
covered by the cancer and open-heart
and, if appropriate, to grant or deny
agreements, these agreements cannot be
CON applications for certain medical
considered part of a ‘‘clearly articulated
services. W. Va. Code § 16–29–11. The
statutory framework grants third parties and affirmatively expressed state
policy.’’ Midcal, 445 U.S. at 105.
the right to intervene to protect their
C. The Cancer and Open-Heart
Agreements Are Not Entitled to Federal
Antitrust Immunity Under the StateAction Doctrine
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
17121
2. The WVHCA Is Not Empowered To
Exercise, and Has Not Exercised, Active
Supervision Over the Cancer and OpenHeart Agreements
The active-supervision requirement of
the state-action doctrine requires that
the State actively supervise and exercise
ultimate control over the challenged
anticompetitive conduct. Midcal, 445
U.S. at 105, Patrick v. Burget, 486 U.S.
94, 100–101 (1988). ‘‘The requirement is
designed to ensure that the state-action
doctrine will shelter only the particular
anticompetitive acts of private parties
that, in the judgment of the State,
actually further state regulatory
policies.’’ Patrick, 486 U.S. at 100–101.
The West Virginia legislature,
however, has not empowered the
WVHCA to require parties to private
agreements to maintain, alter, or
abandon their agreements. Thus, the
WVHCA has no power to exercise active
supervision or control over private
agreements such as the cancer and
open-heart agreements. Moreover, the
WVHCA has not purported to actively
supervise the cancer and open-heart
agreements, as it did not (1) develop a
factual record concerning the initial or
ongoing nature and effect of the
agreements; (2) issue a written decision
approving the agreements; or (3) assess
whether the agreements further criteria
established by the West Virginia
legislature. See FTC v. Ticor Title Ins.
Co., 504 U.S. 621, 637–639 (1992).
The WVHCA, in its February 2000
decision and in the actions of its
officials during 2002, did not purport to
authorize BRMC and PCH to enter into
market-allocation agreements. In its
February 2000 decision denying
BRMC’s cardiac-surgery CON
application, the WVHCA simply stated
a preference that BRMC and PCH work
together to develop a cardiac-surgery
project and encouraged the parties to
submit a cardiac-surgery CON
application that could be approved
under the law. The decision did not
encourage or instruct BRMC and PCH to
allocate cardiac-surgery or cancer
services. Similarly, during meetings in
2002 with representatives of BRMC and
PCH, WVHCA officials neither
instructed nor encouraged BRMC and
PCH to allocate markets or to agree to
anticompetitive conduct such as that
later contained in the cancer and openheart agreements.
Regulation by the WVHCA of the rates
charged by BRMC and PCH, see, e.g., W.
Va. Code § 16–29B–1 et seq., W. Va.
Code St. § 65–5–1 et seq., W. Va. Code
St. R. § 65–26–1 et seq., also does not
satisfy the active-supervision
requirement. In this case, the
E:\FR\FM\04APN1.SGM
04APN1
17122
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
anticompetitive conduct is not the
prices charged by the hospitals; rather,
it is the terms of the cancer and openheart agreements. The WVHCA’s
regulation of rates does not directly
address market-allocation issues or the
potential anticompetitive effects of such
allocations, as rate regulation may fail to
ensure that the hospitals charge rates
equal to those rates that would have
prevailed in a competitive market and it
fails to address decreases in quality of
service, innovation, and consumer
choice that result from an agreement not
to compete.
3. No Virginia Official or Agency
Encouraged or Authorized BRMC and
PCH To Reach an Agreement
Concerning Cardiac-Surgery or Cancer
Services
Although the cancer and open-heart
agreements allocate markets for cancer
and cardiac surgery in three Virginia
counties, no Virginia state action
immunizes the agreements from federal
antitrust review. An extensive
discussion of why the state-action
doctrine does not apply in Virginia is
not necessary as BRMC and PCH has no
contacts with any Virginia agency or
official that might suggest a state-action
defense. No Virginia agency or official
encouraged or authorized BRMC and
PCH to enter into the agreements or
reach any understanding concerning
cardiac-surgery or cancer services.
BRMC and PCH also never sought or
received approval for the agreements
from any Virginia agency or official.
III. Explanation of the Proposed Final
Judgment
The proposed Final Judgment would
enjoin BRMC and PCH from enforcing
any part of the cancer and open-heart
agreements. BRMC and PCH also would
be enjoined from entering into,
continuing, maintaining, or enforcing
any agreement to allocate any cancer or
cardiac-surgery service, market,
territory, or customer. In addition,
BRMC and PCH would be enjoined from
entering into, continuing, maintaining,
or enforcing any other agreement that
(1) prohibits or restricts a health-care
facility from obtaining a certificate of
need relating to cancer services or
cardiac surgery or (2) otherwise
prohibits or restricts a health-care
facility from taking actions related to
providing cancer services or cardiac
surgery without prior notice to and prior
written approval of the United States.
Finally, BRMC and PCH would be
enjoined from entering into, continuing,
maintaining, or enforcing any agreement
with each other concerning cancer
services or cardiac surgery without prior
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
notice to and prior written approval of
the United States. The effect of the
proposed Final Judgment would be to
restore competition between BRMC and
PCH that the cancer and open-heart
agreements eliminated, and would
prevent BRMC and PCH from engaging
in similar conduct in the future.
IV. Remedies Available to Potential
Private Litigants
Section 4 of the Clayton Act, 15
U.S.C. 15, provides that any person who
has been injured as a result of conduct
prohibited by the antitrust laws may
bring suit in federal court to recover
three times the damages suffered, as
well as costs and reasonable attorneys’
fees. Entry of the proposed Final
Judgment will neither impair nor assist
the bringing of such actions. Under the
provisions of section 5(a) of the Clayton
Act, 15 U.S.C. 16(a) the Final Judgment
has no prima facie effect in any
subsequent lawsuits that may be
brought against the Defendant.
V. Procedures Available for
Modifications of the Proposed Final
Judgment
The United States and the Defendant
have stipulated that the proposed Final
Judgment may be entered by the Court
after compliance with the provisions of
the APPA, provided that the United
States has not withdrawn its consent.
The APPA conditions entry upon the
Court’s determination that the proposed
Final Judgment is in the public interest.
The APPA provides a period of at
least sixty days preceding the effective
date of the proposed Final Judgment
within which any person may submit to
the United States written comments
regarding the proposed Final Judgment.
Any person who wishes to comment
should do so within sixty days of the
date of publication of this Competitive
Impact Statement in the Federal
Register. All comments received during
this period will be considered by the
Department of Justice, which remains
free to withdraw its consent to the
proposed Final Judgment at any time
prior to the Court’s entry of judgment.
The comments and the response of the
United States will be filed with the
Court and published in the Federal
Register.
Written comments should be
submitted to: Mark J. Botti, Chief,
Litigation I Section, Antitrust Division,
United States Department of Justice,
1401 H Street, NW., Suite 4000,
Washington, DC 20530.
The proposed Final Judgment
provides that the Court retains
jurisdiction over this action, and the
parties may apply to the Court for any
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
order necessary or appropriate for the
modification, interpretation, or
enforcement of the Final Judgment.
VI. Alternatives to the Proposed Final
Judgment
The United States considered, as an
alternative to the proposed Final
Judgment, a full trial on the merits
against defendants BRMC and PCH. The
United States is satisfied, however, that
the Final Judgment, with its prohibition
on anticompetitive conduct, will more
quickly achieve the primary objectives
of a trial on the merits—reestablishing
competition in the relevant markets.
VII. Standard of Review Under the
APPA for the Proposed Final Judgment
The APPA requires that proposed
consent judgments in antitrust cases
brought by the United States be subject
to a sixty-day comment period, after
which the Court shall determine
whether entry of the proposed Final
Judgment ‘‘is in the public interest.’’ 15
U.S.C. 16(e)(1). In making that
determination, the Court shall consider:
(A) the competitive impact of such judgment,
including termination of alleged violations,
provisions for enforcement and modification,
duration or relief sought, anticipated effects
of alternative remedies actually considered,
whether its terms are ambiguous, and any
other competitive considerations bearing
upon the adequacy of such judgment that the
court deems necessary to a determination of
whether the consent judgment is in the
public interest; and
(B) the impact of entry of such judgment
upon competition in the relevant market or
markets, upon the public generally and
individuals alleging specific injury from the
violations set forth in the complaint
including consideration of the public benefit,
if any, to be derived from a determination of
the issues at trial.
15 U.S.C. § 16(e)(1)(A) and (B). As the
United States Court of Appeals for the
District of Columbia Circuit has held,
the APPA permits a court to consider,
among other things, the relationship
between the remedy secured and the
specific allegations set forth in the
government’s complaint, whether the
decree is sufficiently clear, whether
enforcement mechanisms are sufficient,
and whether the decree may positively
harm third parties. See United States v.
Microsoft Corp., 56 F.3d 1448, 1458–62
(D.C. Cir. 1995).
‘‘Nothing in this section shall be
construed to require the court to
conduct an evidentiary hearing or to
require the court to permit anyone to
intervene.’’ 15 U.S.C. 16(e)(2). Thus, in
conducting this inquiry, ‘‘[t]he court is
nowhere compelled to go to trial or to
engage in extended proceedings which
might have the effect of vitiating the
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
benefits of prompt and less costly
settlement through the consent decree
process.’’ 119 Cong. Rec. 24,598 (1973)
(statement of Senator Tunney).1 Rather:
[a]bsent a showing of corrupt failure of the
government to discharge its duty, the Court,
in making its public interest finding, should
* * * carefully consider the explanations of
the government in the competitive impact
statement and its responses to comments in
order to determine whether those
explanations are reasonable under the
circumstances.
United States v. Mid-America
Dairymen, Inc., 1977–1 Trade Cas.
(CCH) ¶ 61,508, at 71,980 (W.D. Mo.
1977).
Accordingly, with respect to the
adequacy of the relief secured by the
decree, a court may not ‘‘engage in an
unrestricted evaluation of what relief
would best serve the public.’’ United
States v. BNS, Inc., 858 F.2d 456, 462
(9th Cir. 1988) (citing United States v.
Bechtel Corp., 648 F.2d 660, 666 (9th
Cir. 1981)); see also Microsoft, 56 F.3d
at 1460–62. Courts have held that:
[t]he balancing of competing social and
political interests affected by a proposed
antitrust consent decree must be left, in the
first instance, to the discretion of the
Attorney General. The court’s role in
protecting the public interest is one of
insuring that the government has not
breached its duty to the public in consenting
to the decree. The court is required to
determine not whether a particular decree is
the one that will best serve society, but
whether the settlement is ‘‘within the reaches
of the public interest.’’ More elaborate
requirements might undermine the
effectiveness of antitrust enforcement by
consent decree.
Bechtel, 648 F.2d at 666 (emphasis
added) (citations omitted).2
The proposed Final Judgment,
therefore, should not be reviewed under
1 See United States v. Gillette Co., 406 F. Supp.
713, 716 (D. Mass. 1975) (recognizing it was not the
court’s duty to settle; rather, the court must only
answer ‘‘whether the settlement achieved [was]
within the reaches of the public interest’’). A
‘‘public interest’’ determination can be made
properly on the basis of the Competitive Impact
Statement and Response to Comments filed by the
Department of Justice pursuant to the APPA.
Although the APPA authorizes the use of additional
procedures, 15 U.S.C. 16(f), those procedures are
discretionary. A court need not invoke any of them
unless it believes that the comments have raised
significant issues and that further proceedings
would aid the court in resolving those issues. See
H.R. Rep. No. 93–1463, 93rd Cong 2d Sess. 8–9
(1974), reprinted in 1974 U.S.C.C.A.N. 6535, 6538.
2 Cf. BNS, 858 F.2d at 464 (holding that the
court’s ‘‘ultimate authority under the [APPA] is
limited to approving or disapproving the consent
decree’’); Gillette, 406 F. Supp. at 716 (noting that,
in this way, the court is constrained to ‘‘look at the
overall picture not hypercritically, nor with a
microscope, but with an artist’s reducing glass’’).
See generally Microsoft, 56 F3.d at 1461 (discussing
whether ‘‘the remedies [obtained in the decree are]
so inconsonant with the allegations charged as to
fall outside of the ‘reaches of the public interest’’’
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
a standard of whether it is certain to
eliminate every anticompetitive effect of
a particular practice or whether it
mandates certainty of free competition
in the future. Court approval of a final
judgment requires a standard more
flexible and less strict than the standard
required for a finding of liability. ‘‘[A]
proposed decree must be approved even
if it falls short of the remedy the court
would impose on its own, as long as it
falls within the range of acceptability or
is ‘within the reaches of public
interest.’’’ United States v. AT&T, 552 F.
Supp. 131, (D.D.C. 1982) (citations
omitted) (quoting Gillette, 406 F. Supp.
at 716), aff’d sub nom. Maryland v.
United States, 460 U.S. 1001 (1983); see
also United States v. Alcan Aluminum
Ltd., 605 F. Supp. 619, 622 (W.D. Ky.
1985) (approving the consent decree
even though the court would have
imposed a greater remedy).
Moreover, the Court’s role under the
APPA is limited to reviewing the
remedy in relationship to the violations
that the United States has alleged in its
Complaint; the APPA does not authorize
the Court to ‘‘construct [its] own
hypothetical case and then evaluate the
decree against that case.’’ Microsoft, 56
F.3d at 1459. Because the ‘‘court’s
authority to review the decree depends
entirely on the government’s exercising
its prosecurtorial discretion by bringing
a case in the first place,’’ it follows that
‘‘the court is only authorized to review
the decree itself,’’ and not to ‘‘effectively
redraft the complaint’’ to inquire into
other matters that the United States did
not pursue. Id. at 1459–60.
VIII. Determinative Documents
There are no determinative materials
or documents within the meaning of the
APPA that were considered by the
United States in formulating the
proposed Final Judgment.
Dated: March 21, 2005.
Respectfully submitted,
Mark J. Botti,
Chief, Litigation I.
Kasey Warner,
United States Attorney.
Peter J. Mucchetti,
Joan S. Huggler,
Mitchell H. Glende,
Attorneys for the United States, United States
Department of Justice, 1401 H Street, NW.,
Suite 4000, Washington, DC 20530.
Telephone: (202) 353–4211. Facsimile:
(202) 307–5802.
Stephen M. Horn,
Assistant United States Attorney.
[FR Doc. 05–6536 Filed 4–1–05; 8:45 am]
BILLING CODE 4410–11–M
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
17123
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importation of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(1), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(b) authorizing the importation
of such substances, provide
manufacturers holding registrations for
the bulk manufacture of the substances
an opportunity for a hearing.
Therefore, in accordance with Title 21
CFR 1301.34(a), this is notice that on
July 26, 2004, Aveva Drug Delivery
Systems Inc., 3250 Commerce Parkway,
Miramar, Florida 33025–3907, made
application to the Drug Enforcement
Administration (DEA) for registration as
an importer of Fentanyl (9801), a basic
class of controlled substance listed in
Schedule II.
The company plans to import the
listed controlled substance for the
manufacture of analytical reference
standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file written
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 4, 2004.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substance listed in
Schedule I or II are and will continue to
be required to demonstrate to the
Deputy Assistant Administrator, Office
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 70, Number 63 (Monday, April 4, 2005)]
[Notices]
[Pages 17117-17123]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6536]
[[Page 17117]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Proposed Final Judgment and Competitive Impact Statement; United
States v. Bluefield Regional Medical Center, Inc. and Princeton
Community Hospital Associations, Inc.
Notice is hereby given pursuant to the Antitrust Procedures and
Penalties Act, 15 U.S.C. section 16(b)-(h), that a proposed Final
Judgment, Stipulation, and Competitive Impact Statement have been filed
with the United States District Court for the Southern District of West
Virginia in United States v. Bluefield Regional Medical Center, Inc.
and Princeton Community Hospital Association, Inc., Civil Case No.
1:05-0234. On March 21, 2005, the United States filed a Complaint
alleging that, on January 30, 2003, Bluefield Regional Medical Center,
Inc. (BRMC) and Princeton Community Hospital Association, Inc. (PCH)
entered into two agreements in which BRMC agreed not to offer many
cancer services and PCH agreed not to offer cardiac-surgery services.
The BRMC-PCH agreements effectively allocated markets for cancer and
cardiac-surgery services and restrained competition to the detriment of
consumers in violation of section 1 of the Sherman Act.
The proposed Final Judgment filed with the Complaint will enjoin
BRMC and PCH from enforcing the BRMC-PCH agreements. BRMC and PCH also
will be enjoined from entering into, continuing, maintaining, or
enforcing any agreement to allocate markets, territories, or customers
concerning cancer services or cardiac surgery. In addition, BRMC and
PCH will be enjoined from entering into, continuing, maintaining, or
enforcing any other agreement that (1) prohibits or restricts a health-
care facility from obtaining a certificate of need relating to cancer
services or cardiac surgery or (2) otherwise prohibits or restricts a
health-care facility from taking actions related to providing cancer
services or cardiac surgery without prior notice to and prior written
approval of the United States. Finally, BRMC and PCH are enjoined from
entering into, continuing, maintaining, or enforcing any agreement with
each other concerning cancer services or cardiac surgery without prior
notice to and prior written approval of the United States.
Copies of the Complaint, proposed Final Judgment, and Competitive
Impact Statement are available for inspection at the Department of
Justice, Antitrust Documents Group, 325 Seventh Street, NW., Room 215
North, Washington, DC 20530 and at the Office of the Clerk of the
United States District Court for the Southern District of West
Virginia, 601 Federal Street, Room 2303, Bluefield, West Virgina 24701.
Public comment is invited within 60 days of the date of this
notice. Such comments, and responses thereto, will be published in the
Federal Register and filed with the Court. Comments should be directed
to Mark J. Botti, Chief, Litigation I Section, Antitrust Division, U.S.
Department of Justice, 1401 H Street, NW., Suite 4000, Washington, DC
20530 (Telephone (202) 307-0001).
Dorothy B. Fountain,
Deputy Director of Operations, Antitrust Division.
Final Judgment
Whereas, Plaintiff, the United States of America, filed its
Complaint on March 21, 2005 alleging that Defendants, Bluefield
Regional Medical Center, Inc. and Princeton Community Hospital
Association, Inc., entered into agreements in violation of section 1 of
the Sherman Act, 15 U.S.C. 1, and Plaintiff and Defendants, by their
respective attorneys, have consented to the entry of this Final
Judgment without trial or adjudication of any issue of fact or law, and
without this Final Judgment constituting any evidence against, or any
admission by, any party regarding any such issue of fact or law;
And whereas, Defendants agree to be bound by the provisions of the
Final Judgment pending its approval by this Court;
And whereas, the essence of this Final Judgment is to enjoin the
Defendants from allocating markets for the provision of certain medical
services and to restore lost competition as alleged in the Complaint;
And whereas, the United States requires Defendants to agree to
certain procedures and prohibitions for the purpose of restoring the
loss of competition alleged in the Complaint;
Now therefore, before any testimony is taken, without trial or
adjudication of any issue of fact or law, and upon consent of the
parties, it is ordered, adjudged and decreed:
I. Jurisdiction
This Court has jurisdiction over the subject matter of and each of
the parties to this action. The Complaint states a claim upon which
relief may be granted against Defendants under section 1 of the Sherman
Act, as amended (15 U.S.C. 1).
II. Definitions
As used in this Final Judgment:
A. ``Agreement'' means any kind of formal or informal agreement,
arrangement, contract, understanding, memorandum of understanding,
interim contract, contract appendix, addendum, attachment, amendment,
waiver, or modification. Agreements that solely concern patient-
treatment protocols or the transfer of patients necessary to render
patient care that is unavailable at BRMC or PCH shall not be deemed an
agreement within the scope of this Final Judgment. An agreement solely
for the merger of BRMC and PCH, the acquisition by one of the other, or
bringing all or substantially all of the operations or assets of BRMC
and PCH under common control shall not be deemed an agreement within
the scope of this Final Judgment if BRMC and PCH give at least thirty
days advance notice of such merger, acquisition, or transaction to the
United States.
B. ``BRMC'' means Defendant Bluefield Regional Medical Center, Inc.
a non-profit corporation organized and existing under the laws of the
State of West Virginia with its headquarters in Bluefield, West
Virginia, its successors and assigns, and its subsidiaries, divisions,
groups, affiliates, partnerships and joint ventures, and their
directors, officers, managers, agents, and employees.
C. ``Cancer and Open-Heart Agreements'' means (1) the contract
dated January 30, 2003 between BRMC and PCH concerning cancer services
and all amendments and other agreements ancillary to that contract and
(2) the contract dated January 30, 2003 among BRMC, PCH, and Charleston
Area Medical Center, Inc. concerning cardiac surgery and all amendments
and other agreements ancillary to that contract.
D. ``Cancer Services'' means any health or other service relating
to any service performed by cancer specialists such as radiation
oncologists, medical oncologists, surgical oncologists, gynecological
oncologists, and other oncologic physician specialists. This term
includes any equipment, technology, or modality used in providing such
services.
E. ``Cardiac Surgery'' means any health or other services relating
to surgery on the heart or major blood vessels of the heart (including
both open and closed heart surgery) and therapeutic cardiac
catherization. This term includes any service, equipment, technology,
or modality relating to the services of an open-heart surgeon,
cardiovascular surgeon, cardiovascular anesthesiologist, interventional
cardiologist, or perfusionist.
F. ``Certificate of Need'' means certificate of need as recognized
by the
[[Page 17118]]
State of West Virginia (W. Va. Code Sec. 16-2D-1 et seq.) and a
certificate of public need as recognized in the Commonwealth of
Virginia (Va. Code Ann. Sec. 32.1-102.1 et seq.).
G. ``Health-Care Facility'' means any facility providing health-
care services, including hospitals, hospital-owned or managed physician
practices, ambulatory-care centers, clinics, urgent-care centers, free-
standing emergency-care centers, and ambulatory-surgery centers.
H. ``PCH'' means Defendant Princeton Community Hospital
Association, Inc., a non-profit corporation organized and existing
under the laws of the State of West Virginia with its headquarters in
Princeton, West Virginia, its successors and assigns, and its
subsidiaries, divisions, groups, affiliates, partnerships and joint
ventures, and their directors, officers, managers, agents, and
employees.
I. The terms ``and'' and ``or'' have both conjunctive and
disjunctive meanings.
III. Applicability
This Final Judgment applies to BRMC and PCH, as defined above, and
all other persons in active concert or participation with any of them
who receive actual notice of this Final Judgment by personal service or
otherwise.
IV. Prohibited Conduct
A. BRMC and PCH are enjoined from enforcing all or any part of the
Cancer and Open-Heart Agreements. BRMC's and PCH's obligations under
this Final Judgment supersede their obligations under either of these
agreements, and BRMC and PCH shall not object to the performance of
their obligations under this Final Judgment on the grounds that those
obligations would cause them to breach either agreement.
B. BRMC and PCH are enjoined from, in any manner, directly or
indirectly, entering into, continuing, maintaining, or enforcing any
agreement to allocate any cancer or cardiac-surgery service, market,
territory, or customer.
C. BRMC and PCH are enjoined from, in any manner, directly or
indirectly, entering into, continuing, maintaining, or enforcing any
other agreement that (1) prohibits or restricts a health-care facility
from obtaining a certificate of need relating to cancer services or
cardiac surgery or (2) otherwise prohibits or restricts a health-care
facility from taking actions related to providing cancer services or
cardiac surgery without prior notice to and prior written approval of
the United States, which will not be withheld unreasonably.
D. BRMC and PCH are enjoined from, in any manner, directly or
indirectly, entering into, continuing, maintaining, or enforcing any
agreement with each other concerning cancer services or cardiac surgery
without prior notice to and prior written approval of the United
States, which will not be withheld unreasonably.
V. Compliance Inspection
A. For the purposes of determining or securing compliance with this
Final Judgment, or of determining whether the Final Judgment should be
modified or vacated, and subject to any legally recognized privilege,
from time to time duly authorized representatives of the United States
Department of Justice, including consultants and other persons retained
or designated thereby, shall, upon written request of a duly authorized
representative of the Assistant Attorney General in charge of the
Antitrust Division and on reasonable notice to Defendants, be
permitted:
1. Access during Defendants' office hours to inspect and copy, or
at the United States' option, to require that Defendants provide copies
of, all books, ledgers, accounts, records and documents in their
possession, custody, or control relating to any matters contained in
this Final Judgment; and
2. To interview, either informally or on the record, Defendants'
officers, employees, or agents, who may have their individual counsel
present, regarding such matters. The interviews shall be subject to the
reasonable convenience of the interviewee and without restraint or
interference by Defendants.
B. Upon the written request of a duly authorized representative of
the Assistant Attorney General in charge of the Antitrust Division,
Defendants shall submit written reports, under oath if requested,
relating to any of the matters contained in this Final Judgment as may
be requested.
C. No information or documents obtained by the means provided in
this section shall be divulged by Plaintiff to any person other than an
authorized representative of the executive branch of the United States
except in the course of legal proceedings to which the United States is
a party (including grand jury proceedings), or for the purpose of
securing compliance with this Final Judgment, or as otherwise required
by law.
D. If at the time Defendants furnish information or documents to
the United States, they represent and identify in writing the material
in any such information or documents to which a claim of protection may
be asserted under Rule 26(c)(7) of the Federal Rules of Civil
Procedure, and mark each pertinent page of such material, ``Subject to
claim of protection under Rule 26(c)(7) of the Federal Rules of Civil
Procedure,'' then the United States shall give Defendants ten calendar
days notice prior to divulging such material in any legal proceeding
(other than a grand jury proceeding).
VI. Retention of Jurisdiction
This Court retains jurisdiction to enable any party to this Final
Judgment to apply to this Court at any time for further orders and
directions as may be necessary or appropriate to carry out or construe
this Final Judgment, to modify any of its provisions, to enforce
compliance, and to punish violations of its provisions.
VII. Expiration of Final Judgment
Unless this Court grants an extension, this Final Judgment shall
expire ten years from the date of its entry.
VIII. Correspondence
BRMC and PCH shall provide notice and seek prior written approval
as contemplated by this Final Judgment by sending correspondence to
Chief, Litigation I, Antitrust Division, United States Department of
Justice, 1401 H Street, NW., Suite 4000, Washington, DC 20530, or such
other address as the United States shall designate.
IX. Public Interest Determination
Entry of this Final Judgment is in the public interest.
Court approval subject to procedures of Antitrust Procedures and
Penalties Act, 15 U.S.C. Sec. 16.
United States District Judge.
Stipulation
It is stipulated by and between the undersigned parties, by their
respective attorneys, that:
1. The Court has jurisdiction over the subject matter of this
action and each of the parties hereto, and venue of this action is
proper in this District.
2. The parties stipulate that a proposed Final Judgment in the form
attached as Exhibit A may be entered by the Court, upon the motion of
any party or upon the Court's own motion, at any time after compliance
with the requirements of the antitrust Procedures and Penalties Act, 15
U.S.C. 16, and without further notice to any party or other
proceedings, provided that the United States has not withdrawn its
consent, which it may do at any time before the entry of the proposed
final
[[Page 17119]]
Judgment by serving notice thereof on defendants and by filing that
notice with the Court.
3. Defendants shall abide by and comply with the provisions of the
proposed Final Judgment, pending the Judgment's entry by the Court, or
until expiration of time for all appeals of any Court ruling declining
entry of the proposed Final Judgment, and shall, from the date of the
signing of this Stipulation by the parties, comply with all the terms
and provisions of the proposed Final Judgment as though the same were
in full force and effect as an order of the Court.
4. This Stipulation shall apply with equal force and effect to any
amended proposed Final Judgment agreed upon in writing by the parties
and submitted to the Court.
5. In the event (a) the United States has withdrawn its consent, as
provided in section 2 above, or (b) the proposed Final Judgment is not
entered pursuant to this Stipulation, the time has expired for all
appeals of any Court ruling declining entry of the proposed Final
Judgment, and the Court has not otherwise ordered continued compliance
with the terms and provisions of the proposed Final Judgment, then the
parties are released from all further obligations under this
Stipulation, and the making of this Stipulation shall be without
prejudice to any party in this or any other proceeding.
For Plaintiff United States of America:
Dated: March 21, 2005.
Peter J. Mucchetti, Esq.,
Litigation I Section, Antitrust Division, United States Department
of Justice.
For Defendant Bluefield Regional Medical Center, Inc.:
Dated: March 18, 2005.
Arthur N. Lerner, Esq.,
Crowell & Moring LLP, Counsel for Defendant Bluefield Regional
Medical Center, Inc.
For Defendant Princeton Community Hospital Association, Inc.
March 14, 2005.
Kevin E. Grady, Esq.,
Alston & Bird LLP, Counsel for Defendant Princeton Community
Hospital Association, Inc.
Competitive Impact Statement
The United States of America, pursuant to section 2(b) of the
Antitrust Procedures and Penalties Act, (``APPA''), 15 U.S.C. 16(b)-
(h), files this Competitive Impact Statement relating to the proposed
Final Judgment submitted for entry in this civil antitrust proceeding.
I. Nature and Purpose of the Proceeding
On March 21, 2005, the United States filed a civil antitrust
Complaint alleging that Bluefield Regional Medical Center, Inc. (BRMC)
and Princeton Community Hospital Association, Inc. (PCH) had violated
Section 1 of the Sherman Act, 15 U.S.C. 1. BRMC owns and operates a
265-bed, general acute-care hospital in Bluefield, West Virginia. PCH
owns and operates a 211-bed general acute-care hospital in Princeton,
West Virginia. PCH also owns and operates St. Luke's Hospital, LLC (St.
Luke's), a 79-bed, general acute-care hospital in Bluefield, West
Virginia.
The Complaint alleges that, on January 30, 2003, BRMC and PCH
entered into two agreements (the ``cancer and open-heart agreements'')
in which BRMC agreed not to offer certain cancer services and PCH
agreed not to offer certain cardiac-surgery services. The cancer and
open-heart agreements effectively allocated markets for cancer and
cardiac-surgery services and restrained competition to the detriment of
consumers. With the Complaint, the United States, BRMC, and PCH filed
an agreed-upon proposed Final Judgment that annuls the cancer and open-
heart agreements and prohibits BRMC and PCH from taking actions that
would reduce competition between the two hospitals for patients needing
cancer and cardiac-surgery services.
The United States, BRMC, and PCH have agreed that the proposed
Final Judgment may be entered after compliance with the APPA, provided
that the United States has not withdrawn its consent. Entry of the
Final Judgment would terminate the action, except that the Court would
retain jurisdiction to construe, modify, or enforce the Final
Judgment's provisions and to punish violations thereof.
II. Description of Practices and Events Giving Rise to the Alleged
Violations of the Antitrust Laws
A. Services Provided by the Defendants and Events Preceding the
Parties' Cancer and Open-Heart Agreements
At all times relevant to the matters alleged in the Complaint, BRMC
and PCH have been significant competitors in general acute-care
hospital services and in cancer services. PCH is located about fifteen
miles from BRMC. PCH's St. Luke's Hospital is located about two miles
from BRMC. BRMC, PCH, and St. Luke's are the only general acute-care
hospitals in Mercer County, West Virginia.
BRMC and PCH also have been potential competitors in cardiac-
surgery services. BRMC sought to develop cardiac-surgery services since
at least 1999. Similarly, from at least 1999 until PCH agreed not to
compete with BRMC in cardiac-surgery services, PCH sought to develop
cardiac-surgery services by working with other hospitals in southern
West Virginia.
The State of West Virginia and the Commonwealth of Virginia require
that a hospital obtain a certificate of need or a certificate of public
need (collectively, ``CON'') from a state agency before a hospital may
provide either cardiac-surgery services or radiation-therapy services
(using a linear accelerator) for treating patients with cancer. The
West Virginia Health Care Authority (WVHCA) administers the CON program
in West Virginia. The Virginia Department of Health's Certificate of
Public Need Division and regional health planning agencies administer
the CON program in Virginia.
In January 1999, BRMC submitted a CON application to the WVHCA to
develop a cardiac-surgery program in Mercer County, West Virginia. At
that time, neither BRMC, PCH, nor St. Luke's had a CON to operate a
cardiac-surgery program. PCH, St. Luke's, and other hospitals opposed
BRMC's application. PCH and St. Luke's argued, in part, that BRMC's
application should be denied because it did not provide a role for PCH
and St. Luke's in the provision of cardiac-surgery services in southern
West Virginia.
In February 2000, the WVHCA issued a written decision that denied
BRMC's application for a CON to develop a cardiac-surgery program
because BRMC was unable to show that, without working with other
hospitals, it would be able to attract a sufficient number of patients.
In its decision, the WVHCA wrote that PCH, St. Luke's and other
hospitals had:
failed to successfully negotiate with [BRMC] to reach a shared goal.
The goal being to provide advanced cardiology services to the
citizens of southern West Virginia and southwestern Virginia * * *.
[The WVHCA] would have preferred that the parties work together to
present a project that could have been approved under the existing
law. Instead, the parties fought among themselves, failed to resolve
their differences, and in return, the citizens of southern West
Virginia will be inconvenienced and suffer by not having a regional
open-heart service provider.
On one or more occasions during 2002, BRMC and PCH representatives
met with WVHCA officials. The WVHCA officials encouraged BRMC and PCH
to reach an understanding that would enable the parties to submit an
application for an open-heart surgery
[[Page 17120]]
CON that the WVHCA would be able to approve. The WVHCA officials,
however, neither instructed nor encouraged BRMC and PCH to allocate
markets.
B. The Cancer and Open-Heart Agreements
On January 30, 2003, BRMC and PCH entered into the cancer and open-
heart agreements. The cancer agreement concerned PCH's provision of
certain cancer services, including radiation-therapy services, and the
open-heart agreement concerned BRMC's plan to develop cardiac-surgery
services (open-heart surgery and therapeutic cardiac-catheterization
services). The agreements applied to McDowell, Mercer, Monroe, Raleigh,
Summers, and Wyoming counties in southern West Virginia and Bland,
Giles, and Tazewell counties in western Virginia. In the agreements,
BRMC agreed to submit a joint CON application with PCH to transfer
BRMC's CON to operate radiation-therapy equipment to PCH. PCH agreed to
submit a joint CON application with BRMC for BRMC to receive a cardiac-
surgery CON.
As part of the cancer and open-heart agreements, BRMC agreed to
refrain from competing with PCH in various ways, none of which was
related to a procompetitive purpose. BRMC agreed, among other things:
Not to apply for, finance, encourage, or participate in a
CON to provide cancer services by itself or with any entity other than
PCH;
That, in the event that the State of West Virginia or the
Commonwealth of Virginia no longer requires a CON to provide cancer
services, BRMC would not develop, finance, encourage, participants in,
or support the development or provision of cancer services by BRMC or
any entity other than PCH;
Not to engage in, support, finance, encourage, or
participate in the recruitment of any physician cancer specialists to
BRMC's medical staff or for any other entity or individual, other than
PCH;
To provide to PCH information relating to cancer services
provided by BRMC;
Not to market or advertise that BRMC has a cancer center;
Not to provide outpatient chemotherapy services (except
for those services ordered or performed by either of two physicians
currently practicing at BRMC);
Not to lease space in its existing or future medical
office buildings to any cancer specialists, except for those cancer
specialists leasing space as of the date of the agreement; and
That, in the event that any new technology or modality for
the diagnosis or treatment of cancer becomes available that is not
offered generally at hospitals similar to PCH and BRMC, BRMC would not
acquire, develop, offer or provide such technology or modality, and
BRMC would not finance, encourage, participate in, or support the
development or offering of such technology or modality by any entity
other than PCH.
As part of the cancer and open-heart agreements, PCH also agreed to
refrain from competing with BRMC is various ways, none of which was
related to a procompetitive purpose. PCH agreed, among other things:
Not to apply for, finance, encourage, or participate in a
CON to provide cardiac-surgery services by itself or with any entity
other than BRMC;
That, in the event that the State of West Virginia or the
Commonwealth of Virginia no longer requires a CON to provide cardiac-
surgery services, PCH would not develop, finance, encourage,
participate in, or support the development or provision of cardiac-
surgery services by PCH or any entity other than BRMC;
Not to engage in, support, finance, encourage, or
participate in the recruitment of any cardiac-surgery specialists to
PCH's medical staff or for any other entity or individual, other than
BRMC;
To provide to BRMC information relating services provided
by PCH;
Not to solicit, entertain, finance, aid, support, or
participate in any competing proposal from any entity or physician to
develop cardiac-surgery services;
Not to lease space in its existing or future medical
office buildings to any open-heart surgery specialist; and
That, in the event that any new technology or modality for
the diagnosis or treatment or cardiovascular disease becomes available
that is not offered generally at hospitals similar to PCH and BRMC, PCH
would not acquire, develop, offer or provide such technology or
modality, and PCH would not finance, encourage, participate in, or
support the development or offering of such technology or modality by
any entity other than BRMC.
The term of the cancer and open-heart agreements commend on January
30, 2003 and terminates five years after the first open-heart surgery
is performed at BRMC or the first cancer patient is treated at a PCH
comprehensive cancer center, whichever is later. Neither agreement can
last longer than eight years. Each agreement automatically terminates
if, within three years from commencement, either party has not received
all government approvals needed to provide its services.
PCH and BRMC structured the agreements such that PCH would
independently own its cancer-treatment facilities and provide its
cancer services independently of BRMC, BRMC would independently own its
cardiac-surgery facilities and provide its cardiac-surgery services
independently of PCH, and BRMC and PCH would not provide these services
as part of a joint venture.
On January 23, 2003, BRMC submitted to the WVHCA a CON application,
with PCH as a joint applicant, to develop a cardiac-surgery program at
BRMC. On July 30, 2003, PCH submitted to the WVHCA an application, with
BRMC as a joint applicant, to transfer BRMC's CON to operate radiation-
therapy equipment to PCH. The WVHCA approved BRMC's cardiac-surgery CON
application on August 1, 2003. PCH's application to transfer BRMC's
radiation-therapy equipment CON to PCH remains pending with the WVHCA.
Because of the cancer and open-heart agreements, BRMC and PCH have
refrained and, if not enjoined, likely would continue to refrain from
competing to serve patients that need cancer and cardiac-surgery
services. The cancer and open-heart agreements have had and, unless
enjoined, likely would have the following harmful effects:
Managed-care purchasers, their enrollees and employees,
and other patients in southern West Virginia and western Virginia have
been denied and would be denied the benefits of price competition
between PCH and BRMC;
The quality of services has decreased and likely would
decrease in the absence of competition between PCH and BRMC to provide
cancer and cardiac-surgery services;
Patients have lost and would lose the ability to choose
between PCH and BRMC when selecting a hospital to provide cancer
services;
Patients have lost and would lose the benefit of potential
competition between PCH and BRMC in cardiac-surgery services; and
PCH's and BRMC's incentives to innovate or offer new
cancer and cardiac-surgery services have been and would be decreased.
[[Page 17121]]
C. The Cancer and Open-Heart Agreements Are Not Entitled to Federal
Antitrust Immunity Under the State-Action Doctrine
The state-action doctrine provides immunity from Federal antitrust
liability where a party can satisfy a two-part test. First, the party
must show that the challenged restraint is one clearly articulated and
affirmatively expressed as state policy. California Retail Liquor
Dealers Association v. Midcal Aluminum, 445 U.S. 97, 105 (1980). To
satisfy the clear-articulation requirement, a defendant must show only
that ``the legislature contemplated the kind of action complained of.''
Town of Hallie v. City of Eau Claire, 471 U.S. 34, 44 (1985). Second,
the state must actively supervise the challenged conduct. Midcal, 445
U.S. at 105.
As discussed below, no state action in either West Virginia or
Virginia shields the cancer and open-heart agreements from federal
antitrust review. The West Virginia legislature has not enpowered the
WVHCA to authorize hospitals to enter into market-allocation
agreements. Furthermore, the WVHCA is not empowered to exercise, and
has not exercised, active supervision over the cancer and open-heart
agreements. Indeed, the WVHCA did not purport to authorize the parties
to enter into the agreements. Similarly, in Virginia, no state agency
or official encouraged or authorized BRMC and PCH to reach an
understanding or agreement concerning cardiac-surgery or cancer
services.
1. The West Virginia Legislature Did Not Empower the WVHCA To Authorize
Private Market-allocation Agreements
The West Virginia legislature empowered the WVHCA to administer
West Virginia's CON program according to legislatively established
criteria. W. Va. Code Sec. 16-2D-1 et seq., W. Va. Code St. R. Sec.
65-7-1 et seq., W. Va. Code Sec. 16-29B-1 et seq. Although the West
Virginia legislature granted the WVHCA significant regulatory powers
over competition in West Virginia health-care markets, it limited the
means by which the WCHCA can regulate competition among health-care
providers principally to granting or denying CONs to firms wishing to
compete. W. Va. Code Sec. 16-2D-1 et seq., W. Va. Code St. R. Sec.
65-7-1 et seq., W. Va. Code Sec. 16-29B-1 et seq.
In administering the CON program, the WVHCA is called upon to
review and, if appropriate, to grant or deny CON applications for
certain medical services. W. Va. Code Sec. 16-29-11. The statutory
framework grants third parties the right to intervene to protect their
interests; affords adversely affected parties the right of judicial
review; requires written findings as to whether approval of a CON would
further legislatively established criteria; and establishes other
procedural safeguards. W. Va. Code Sec. Sec. 16-29B-12(f), 16-29B-13,
and 16-2D-9. When reviewing CON applications, the WVHCA must follow
established procedures and act within the CON process. See W. Va. Code
Sec. 16-2D-1 et seq., W. Va. Code St. R. Sec. 65-7-1 et seq., W. Va.
Code Sec. 16-29B-1 et seq. The statutes and regulations delineating
the responsibilities of the WVHCA do not explicitly empower it to
consider, or to issue opinions concerning, private market-allocation
agreements. See, e.g., W. Va. Code Sec. 16-2D-1 et seq., W. Va. Code
St. R. Sec. 65-7-1 et seq., W. Va. Code Sec. 16-29B-1 et seq., W. Va.
Code St. R. Sec. 65-5-1 et seq., W. Va. Code St. R. Sec. 65-26-1 et
seq.
Nor does the WVHCA have implicit authority to approve private
agreements as a means of regulating competition. In light of the rights
and procedural safeguards afforded in the statutory framework to
affected parties, to conclude that WVHCA has implied authority to
authorize private market-allocation agreements would be inconsistent
with that framework and effectively would give to the WVHCA
unreviewable discretion to regulate health-care markets. To the
contrary, the legislature generally has left West Virginia health-care
providers free to make market decisions on how to compete as long as
they are not (1) adding or expanding health-care services; (2)
incurring a capital expenditure of $2 million or more; (3) obtaining
major medical equipment valued at $2 million or more; or (4) developing
or acquiring new health-care facilities. W. Va. Code Sec. 16-2D-3.
Because the West Virginia legislature has not granted to the WVHCA
the explicit authority to approve private market-allocation agreements
such as the cancer and open-heart agreements, because any implicit
authority of the WVHCA to approve such agreements would be inconsistent
with the statutory framework that the legislature did create, and
because the legislature clearly contemplated that West Virginia
hospitals would compete in the free market for many of the activities
covered by the cancer and open-heart agreements, these agreements
cannot be considered part of a ``clearly articulated and affirmatively
expressed state policy.'' Midcal, 445 U.S. at 105.
2. The WVHCA Is Not Empowered To Exercise, and Has Not Exercised,
Active Supervision Over the Cancer and Open-Heart Agreements
The active-supervision requirement of the state-action doctrine
requires that the State actively supervise and exercise ultimate
control over the challenged anticompetitive conduct. Midcal, 445 U.S.
at 105, Patrick v. Burget, 486 U.S. 94, 100-101 (1988). ``The
requirement is designed to ensure that the state-action doctrine will
shelter only the particular anticompetitive acts of private parties
that, in the judgment of the State, actually further state regulatory
policies.'' Patrick, 486 U.S. at 100-101.
The West Virginia legislature, however, has not empowered the WVHCA
to require parties to private agreements to maintain, alter, or abandon
their agreements. Thus, the WVHCA has no power to exercise active
supervision or control over private agreements such as the cancer and
open-heart agreements. Moreover, the WVHCA has not purported to
actively supervise the cancer and open-heart agreements, as it did not
(1) develop a factual record concerning the initial or ongoing nature
and effect of the agreements; (2) issue a written decision approving
the agreements; or (3) assess whether the agreements further criteria
established by the West Virginia legislature. See FTC v. Ticor Title
Ins. Co., 504 U.S. 621, 637-639 (1992).
The WVHCA, in its February 2000 decision and in the actions of its
officials during 2002, did not purport to authorize BRMC and PCH to
enter into market-allocation agreements. In its February 2000 decision
denying BRMC's cardiac-surgery CON application, the WVHCA simply stated
a preference that BRMC and PCH work together to develop a cardiac-
surgery project and encouraged the parties to submit a cardiac-surgery
CON application that could be approved under the law. The decision did
not encourage or instruct BRMC and PCH to allocate cardiac-surgery or
cancer services. Similarly, during meetings in 2002 with
representatives of BRMC and PCH, WVHCA officials neither instructed nor
encouraged BRMC and PCH to allocate markets or to agree to
anticompetitive conduct such as that later contained in the cancer and
open-heart agreements.
Regulation by the WVHCA of the rates charged by BRMC and PCH, see,
e.g., W. Va. Code Sec. 16-29B-1 et seq., W. Va. Code St. Sec. 65-5-1
et seq., W. Va. Code St. R. Sec. 65-26-1 et seq., also does not
satisfy the active-supervision requirement. In this case, the
[[Page 17122]]
anticompetitive conduct is not the prices charged by the hospitals;
rather, it is the terms of the cancer and open-heart agreements. The
WVHCA's regulation of rates does not directly address market-allocation
issues or the potential anticompetitive effects of such allocations, as
rate regulation may fail to ensure that the hospitals charge rates
equal to those rates that would have prevailed in a competitive market
and it fails to address decreases in quality of service, innovation,
and consumer choice that result from an agreement not to compete.
3. No Virginia Official or Agency Encouraged or Authorized BRMC and PCH
To Reach an Agreement Concerning Cardiac-Surgery or Cancer Services
Although the cancer and open-heart agreements allocate markets for
cancer and cardiac surgery in three Virginia counties, no Virginia
state action immunizes the agreements from federal antitrust review. An
extensive discussion of why the state-action doctrine does not apply in
Virginia is not necessary as BRMC and PCH has no contacts with any
Virginia agency or official that might suggest a state-action defense.
No Virginia agency or official encouraged or authorized BRMC and PCH to
enter into the agreements or reach any understanding concerning
cardiac-surgery or cancer services. BRMC and PCH also never sought or
received approval for the agreements from any Virginia agency or
official.
III. Explanation of the Proposed Final Judgment
The proposed Final Judgment would enjoin BRMC and PCH from
enforcing any part of the cancer and open-heart agreements. BRMC and
PCH also would be enjoined from entering into, continuing, maintaining,
or enforcing any agreement to allocate any cancer or cardiac-surgery
service, market, territory, or customer. In addition, BRMC and PCH
would be enjoined from entering into, continuing, maintaining, or
enforcing any other agreement that (1) prohibits or restricts a health-
care facility from obtaining a certificate of need relating to cancer
services or cardiac surgery or (2) otherwise prohibits or restricts a
health-care facility from taking actions related to providing cancer
services or cardiac surgery without prior notice to and prior written
approval of the United States. Finally, BRMC and PCH would be enjoined
from entering into, continuing, maintaining, or enforcing any agreement
with each other concerning cancer services or cardiac surgery without
prior notice to and prior written approval of the United States. The
effect of the proposed Final Judgment would be to restore competition
between BRMC and PCH that the cancer and open-heart agreements
eliminated, and would prevent BRMC and PCH from engaging in similar
conduct in the future.
IV. Remedies Available to Potential Private Litigants
Section 4 of the Clayton Act, 15 U.S.C. 15, provides that any
person who has been injured as a result of conduct prohibited by the
antitrust laws may bring suit in federal court to recover three times
the damages suffered, as well as costs and reasonable attorneys' fees.
Entry of the proposed Final Judgment will neither impair nor assist the
bringing of such actions. Under the provisions of section 5(a) of the
Clayton Act, 15 U.S.C. 16(a) the Final Judgment has no prima facie
effect in any subsequent lawsuits that may be brought against the
Defendant.
V. Procedures Available for Modifications of the Proposed Final
Judgment
The United States and the Defendant have stipulated that the
proposed Final Judgment may be entered by the Court after compliance
with the provisions of the APPA, provided that the United States has
not withdrawn its consent. The APPA conditions entry upon the Court's
determination that the proposed Final Judgment is in the public
interest.
The APPA provides a period of at least sixty days preceding the
effective date of the proposed Final Judgment within which any person
may submit to the United States written comments regarding the proposed
Final Judgment. Any person who wishes to comment should do so within
sixty days of the date of publication of this Competitive Impact
Statement in the Federal Register. All comments received during this
period will be considered by the Department of Justice, which remains
free to withdraw its consent to the proposed Final Judgment at any time
prior to the Court's entry of judgment. The comments and the response
of the United States will be filed with the Court and published in the
Federal Register.
Written comments should be submitted to: Mark J. Botti, Chief,
Litigation I Section, Antitrust Division, United States Department of
Justice, 1401 H Street, NW., Suite 4000, Washington, DC 20530.
The proposed Final Judgment provides that the Court retains
jurisdiction over this action, and the parties may apply to the Court
for any order necessary or appropriate for the modification,
interpretation, or enforcement of the Final Judgment.
VI. Alternatives to the Proposed Final Judgment
The United States considered, as an alternative to the proposed
Final Judgment, a full trial on the merits against defendants BRMC and
PCH. The United States is satisfied, however, that the Final Judgment,
with its prohibition on anticompetitive conduct, will more quickly
achieve the primary objectives of a trial on the merits--reestablishing
competition in the relevant markets.
VII. Standard of Review Under the APPA for the Proposed Final Judgment
The APPA requires that proposed consent judgments in antitrust
cases brought by the United States be subject to a sixty-day comment
period, after which the Court shall determine whether entry of the
proposed Final Judgment ``is in the public interest.'' 15 U.S.C.
16(e)(1). In making that determination, the Court shall consider:
(A) the competitive impact of such judgment, including termination
of alleged violations, provisions for enforcement and modification,
duration or relief sought, anticipated effects of alternative
remedies actually considered, whether its terms are ambiguous, and
any other competitive considerations bearing upon the adequacy of
such judgment that the court deems necessary to a determination of
whether the consent judgment is in the public interest; and
(B) the impact of entry of such judgment upon competition in the
relevant market or markets, upon the public generally and
individuals alleging specific injury from the violations set forth
in the complaint including consideration of the public benefit, if
any, to be derived from a determination of the issues at trial.
15 U.S.C. Sec. 16(e)(1)(A) and (B). As the United States Court of
Appeals for the District of Columbia Circuit has held, the APPA permits
a court to consider, among other things, the relationship between the
remedy secured and the specific allegations set forth in the
government's complaint, whether the decree is sufficiently clear,
whether enforcement mechanisms are sufficient, and whether the decree
may positively harm third parties. See United States v. Microsoft
Corp., 56 F.3d 1448, 1458-62 (D.C. Cir. 1995).
``Nothing in this section shall be construed to require the court
to conduct an evidentiary hearing or to require the court to permit
anyone to intervene.'' 15 U.S.C. 16(e)(2). Thus, in conducting this
inquiry, ``[t]he court is nowhere compelled to go to trial or to engage
in extended proceedings which might have the effect of vitiating the
[[Page 17123]]
benefits of prompt and less costly settlement through the consent
decree process.'' 119 Cong. Rec. 24,598 (1973) (statement of Senator
Tunney).\1\ Rather:
---------------------------------------------------------------------------
\1\ See United States v. Gillette Co., 406 F. Supp. 713, 716 (D.
Mass. 1975) (recognizing it was not the court's duty to settle;
rather, the court must only answer ``whether the settlement achieved
[was] within the reaches of the public interest''). A ``public
interest'' determination can be made properly on the basis of the
Competitive Impact Statement and Response to Comments filed by the
Department of Justice pursuant to the APPA. Although the APPA
authorizes the use of additional procedures, 15 U.S.C. 16(f), those
procedures are discretionary. A court need not invoke any of them
unless it believes that the comments have raised significant issues
and that further proceedings would aid the court in resolving those
issues. See H.R. Rep. No. 93-1463, 93rd Cong 2d Sess. 8-9 (1974),
reprinted in 1974 U.S.C.C.A.N. 6535, 6538.
[a]bsent a showing of corrupt failure of the government to discharge
its duty, the Court, in making its public interest finding, should *
* * carefully consider the explanations of the government in the
competitive impact statement and its responses to comments in order
to determine whether those explanations are reasonable under the
---------------------------------------------------------------------------
circumstances.
United States v. Mid-America Dairymen, Inc., 1977-1 Trade Cas. (CCH) ]
61,508, at 71,980 (W.D. Mo. 1977).
Accordingly, with respect to the adequacy of the relief secured by
the decree, a court may not ``engage in an unrestricted evaluation of
what relief would best serve the public.'' United States v. BNS, Inc.,
858 F.2d 456, 462 (9th Cir. 1988) (citing United States v. Bechtel
Corp., 648 F.2d 660, 666 (9th Cir. 1981)); see also Microsoft, 56 F.3d
at 1460-62. Courts have held that:
[t]he balancing of competing social and political interests affected
by a proposed antitrust consent decree must be left, in the first
instance, to the discretion of the Attorney General. The court's
role in protecting the public interest is one of insuring that the
government has not breached its duty to the public in consenting to
the decree. The court is required to determine not whether a
particular decree is the one that will best serve society, but
whether the settlement is ``within the reaches of the public
interest.'' More elaborate requirements might undermine the
effectiveness of antitrust enforcement by consent decree.
Bechtel, 648 F.2d at 666 (emphasis added) (citations omitted).\2\
---------------------------------------------------------------------------
\2\ Cf. BNS, 858 F.2d at 464 (holding that the court's
``ultimate authority under the [APPA] is limited to approving or
disapproving the consent decree''); Gillette, 406 F. Supp. at 716
(noting that, in this way, the court is constrained to ``look at the
overall picture not hypercritically, nor with a microscope, but with
an artist's reducing glass''). See generally Microsoft, 56 F3.d at
1461 (discussing whether ``the remedies [obtained in the decree are]
so inconsonant with the allegations charged as to fall outside of
the `reaches of the public interest'''
---------------------------------------------------------------------------
The proposed Final Judgment, therefore, should not be reviewed
under a standard of whether it is certain to eliminate every
anticompetitive effect of a particular practice or whether it mandates
certainty of free competition in the future. Court approval of a final
judgment requires a standard more flexible and less strict than the
standard required for a finding of liability. ``[A] proposed decree
must be approved even if it falls short of the remedy the court would
impose on its own, as long as it falls within the range of
acceptability or is `within the reaches of public interest.''' United
States v. AT&T, 552 F. Supp. 131, (D.D.C. 1982) (citations omitted)
(quoting Gillette, 406 F. Supp. at 716), aff'd sub nom. Maryland v.
United States, 460 U.S. 1001 (1983); see also United States v. Alcan
Aluminum Ltd., 605 F. Supp. 619, 622 (W.D. Ky. 1985) (approving the
consent decree even though the court would have imposed a greater
remedy).
Moreover, the Court's role under the APPA is limited to reviewing
the remedy in relationship to the violations that the United States has
alleged in its Complaint; the APPA does not authorize the Court to
``construct [its] own hypothetical case and then evaluate the decree
against that case.'' Microsoft, 56 F.3d at 1459. Because the ``court's
authority to review the decree depends entirely on the government's
exercising its prosecurtorial discretion by bringing a case in the
first place,'' it follows that ``the court is only authorized to review
the decree itself,'' and not to ``effectively redraft the complaint''
to inquire into other matters that the United States did not pursue.
Id. at 1459-60.
VIII. Determinative Documents
There are no determinative materials or documents within the
meaning of the APPA that were considered by the United States in
formulating the proposed Final Judgment.
Dated: March 21, 2005.
Respectfully submitted,
Mark J. Botti,
Chief, Litigation I.
Kasey Warner,
United States Attorney.
Peter J. Mucchetti,
Joan S. Huggler,
Mitchell H. Glende,
Attorneys for the United States, United States Department of
Justice, 1401 H Street, NW., Suite 4000, Washington, DC 20530.
Telephone: (202) 353-4211. Facsimile: (202) 307-5802.
Stephen M. Horn,
Assistant United States Attorney.
[FR Doc. 05-6536 Filed 4-1-05; 8:45 am]
BILLING CODE 4410-11-M